Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion

NCT03347396 is registered in ClinicalTrials.gov with Bioverativ, a Sanofi company as lead sponsor.

NCT NCT03347396
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03347396 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion
Lead sponsor
Bioverativ, a Sanofi company
Phase
Phase 3
Overall status
Completed
Start date
March 5, 2018
Completion date
October 5, 2021
Enrollment
24 (actual)
Sites
49

Conditions

As the registry lists them; a condition with its own page is linked.

agglutinin disease, cold